Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives.

By K. Knop, Richard Hoogenboom, D. Fischer, Ulrich S. Schubert. Angewandte Chemie, 2010

3,209 citations recorded by the source corpus.

Subfields: Biomaterials, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/11beaab3d5827d0b6d633f678974e8c975229e4c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Pharmaceutical Science

Citations in the corpus

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery (2015, positive): “Other poly(amino acid)-based coatings, including 3 kDa poly(hydroxyethyl-L-asparagine) and 4 kDa poly(hydroxyethyl-L-glutamine), have facilitated prolonged liposome circulation in the blood, but ABC comparable to 5 kDa PEGylated liposomes was also observed [81].”
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review (2018, background): “This twist is known as the PEGylation dilemma [23,24].”
Nanoparticle PEGylation for imaging and therapy (2011, background): “Despite these achievements, a number of limitations and challenges still hamper complete deployment of PEG [12].”
The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “It is not the objective of this review to cover surface modification strategies, (see refs, [33,35,67,68] for more information on this topic) but PEGylation still remains today the gold standard to impart CDCs with long circulation times [69,70].”
Bioinspired Poly(2-oxazoline)s (2011, background): “other emerging applications of poly(2-oxazoline)s, for instance in the fields of biomedicine and life sciences, where POXylation is being successfully introduced as an alternative to PEGylation [14],”
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. (2016, neutral): “Adagen®, pegadamase 96-126 5 [11-17] Patient d”
Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “However, it is important to note that there are still possible negative side effects including an immunological response through complement activation, toxicity of side products, and possible accumulation of PEG due to its non-biodegradability [94].”